Welcome to our dedicated page for iRhythm Holdings SEC filings (Ticker: IRTC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The iRhythm Technologies, Inc. (NASDAQ: IRTC) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a public issuer. As a digital health care company focused on ambulatory cardiac monitoring and data analytics, iRhythm uses its SEC reports to communicate financial performance, risk factors, governance matters, and material corporate events related to its Zio long-term continuous monitoring (LTCM) service and broader operations.
Investors can use this page to review current and historical filings retrieved from the SEC’s EDGAR system, including annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K. Recent 8-K filings have covered topics such as quarterly financial results, investor presentations, and amendments to the Executive Change in Control and Severance Policy, which outlines severance payments, COBRA coverage, and equity vesting treatment for senior leaders under specified termination scenarios.
For those analyzing iRhythm’s business in more depth, the company’s periodic reports typically discuss revenue from Zio services, gross margins, operating expenses, non-GAAP measures like adjusted EBITDA and adjusted net loss, and liquidity metrics such as cash, cash equivalents, and marketable securities. These documents also describe how iRhythm accounts for items like stock-based compensation, business transformation costs, and other adjustments that affect non-GAAP results.
Stock Titan enhances access to these filings with AI-powered summaries that help explain the key points of lengthy documents, such as 10-K and 10-Q reports, in more accessible language. Users can quickly identify major changes in financial condition, updates to risk disclosures, and details of insider or executive-related arrangements that appear in forms and exhibits. This combination of real-time filing access and AI-generated insights can support investors, analysts, and other stakeholders who want to understand how iRhythm reports on its digital cardiac monitoring business and corporate governance over time.
iRhythm Holdings, Inc. reported that President and CEO Quentin S. Blackford acquired 31,842 shares of common stock through a grant of Restricted Stock Units (RSUs). Each RSU represents the right to receive one share of common stock if vesting conditions are met. Following this award, he directly holds 217,968 shares. According to the grant terms, 25% of the RSUs vest on March 1, 2027 and on each one-year anniversary after that date, as long as he continues as a service provider.
Patterson Chad reported acquisition or exercise transactions in this Form 4 filing.
iRhythm Holdings, Inc. reported that Chief Commercial & Product Officer Chad Patterson received an equity award in the form of restricted stock units. He was granted 10,870 RSUs, each representing a contingent right to receive one share of iRhythm common stock at no cash cost.
According to the vesting schedule, 25% of the RSUs vest on March 1, 2027, with additional 25% portions vesting on each one-year anniversary thereafter, as long as he continues as a service provider through each vesting date. Following this grant, his reported direct ownership increased to 62,608 shares of common stock.
Rosenbaum Marc Wade reported acquisition or exercise transactions in this Form 4 filing.
iRhythm Holdings, Inc. reported that Chief Accounting Officer Marc Wade Rosenbaum received a grant of 2,508 Restricted Stock Units (RSUs) of common stock on February 25, 2026. Each RSU represents one share, with 25% vesting on March 1, 2027 and on each following one-year anniversary, subject to continued service. Following this award, his directly held common stock position is 17,522 shares.
Murphy Patrick Michael reported acquisition or exercise transactions in this Form 4 filing.
iRhythm Holdings executive Patrick Michael Murphy, the company’s CBO and CLO, received an equity award covering 7,024 shares of common stock in the form of Restricted Stock Units (RSUs). Each RSU represents a right to receive one share of common stock at vesting.
According to the filing, 25% of the RSUs vest on March 1, 2027, with an additional 25% vesting on each one-year anniversary thereafter, as long as he continues as a service provider through each vesting date. Following this grant, he holds 67,560 shares of common stock directly.
Smith Mervin reported acquisition or exercise transactions in this Form 4 filing.
iRhythm Holdings EVP Strategic Business Ops Mervin Smith received an equity award of 6,689 restricted stock units of common stock. These RSUs were granted on February 25, 2026 at no cash cost. 25% of the units vest on March 1, 2027 and on each one-year anniversary after that, so long as he continues as a service provider. Following this award, he directly holds 26,964 shares of common stock.
iRhythm Holdings, Inc. executive Sean Clinton Freeman, EVP of Strategy & Corporate Development, reported an equity award on Form 4. He acquired 7,525 shares of common stock through a grant of Restricted Stock Units at a stated price of $0.00 per unit, bringing his directly held total to 14,286 shares after the grant. The RSUs vest over four years, with 25% vesting on March 1, 2027 and additional 25% installments on each one-year anniversary, so long as he continues as a service provider through each vesting date.
Shrishrimal Sumi reported acquisition or exercise transactions in this Form 4 filing.
iRhythm Holdings, Inc. executive Sumi Shrishrimal, EVP and Chief Risk Officer, received a grant of 5,518 shares of Common Stock in the form of Restricted Stock Units (RSUs) on February 25, 2026 at a stated price of $0.00 per share. Following this equity award, her directly held common stock position is reported as 44,700 shares. Each RSU represents a right to receive one share of common stock, with 25% of the RSUs scheduled to vest on March 1, 2027 and the remaining RSUs vesting in equal installments on each one-year anniversary thereafter, contingent on her continued service.
Lawrence Brian Lee reported acquisition or exercise transactions in this Form 4 filing.
iRhythm Holdings Chief Technology Officer Lawrence Brian Lee reported receiving an equity award tied to the company’s common stock. He was granted 6,689 Restricted Stock Units (RSUs), each representing a contingent right to receive one share of common stock for no cash payment.
According to the award terms, 25% of the RSUs vest on March 1, 2027 and on each one-year anniversary thereafter, as long as he continues as a service provider through each vesting date. After this grant, Lee directly holds 21,168 shares of common stock, reflecting his increased equity-based stake in the company.
iRhythm Holdings Chief Financial Officer Daniel G. Wilson reported RSU vesting and related share sales. On February 24, 2026, he acquired 9,412 shares of common stock at no cost upon the Compensation & Human Capital Management Committee determining performance RSU conditions were met. On February 25, 2026, he sold 5,188 shares at an average price of $135.4189 to cover tax withholding and remittance obligations from the RSU vesting. After these transactions, he directly held 30,694 shares and indirectly held 100 shares through The Wilson Living Trust, where he serves as trustee.
iRhythm Holdings executive Minang Turakhia, Chief Medical/Scientific Officer and EVP Advanced Technology, reported a mix of equity award and related share sale. On February 24, 2026, he acquired 15,060 shares of common stock at $0.00 per share through the vesting of performance RSUs granted on February 27, 2023, after the compensation committee determined the performance conditions were met. On February 25, 2026, he sold 7,804 shares at an average price of $135.4189 per share to cover tax withholding and remittance obligations tied to this vesting. Following these transactions, he directly held 48,899 shares of iRhythm common stock.